A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands

S.E.M. Veldhuijzen van Zanten; M.H.A. Jansen; E. Sanchez Aliaga; D.G. van Vuurden; W.P. Vandertop; G.J.L. Kaspers

doi:10.1586/14737140.2015.974563

A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands

S.E.M. Veldhuijzen van Zanten, M.H.A. Jansen, E. Sanchez Aliaga, D.G. van Vuurden, W.P. Vandertop, G.J.L. Kaspers

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

INTRODUCTION: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.

METHODS: We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.

RESULTS: The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.

DISCUSSION: Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.

Original language	English
Pages (from-to)	157-64
Number of pages	8
Journal	Expert Review of Anticancer Therapy
Volume	15
Issue number	2
DOIs	https://doi.org/10.1586/14737140.2015.974563
Publication status	Published - 2015

Access to Document

10.1586/14737140.2015.974563

Cite this

@article{7415a462722c46a99a0548f0a785bce8,

title = "A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands",

abstract = "INTRODUCTION: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.METHODS: We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.RESULTS: The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.DISCUSSION: Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.",

keywords = "Brain Stem Neoplasms/diagnosis, Child, Child, Preschool, Cohort Studies, Female, Glioma/diagnosis, Humans, Male, Netherlands, Pons/pathology, Prognosis, Retrospective Studies, Survival Rate",

author = "{Veldhuijzen van Zanten}, S.E.M. and M.H.A. Jansen and {Sanchez Aliaga}, E. and {van Vuurden}, D.G. and W.P. Vandertop and G.J.L. Kaspers",

year = "2015",

doi = "10.1586/14737140.2015.974563",

language = "English",

volume = "15",

pages = "157--64",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands

AU - Veldhuijzen van Zanten, S.E.M.

AU - Jansen, M.H.A.

AU - Sanchez Aliaga, E.

AU - van Vuurden, D.G.

AU - Vandertop, W.P.

AU - Kaspers, G.J.L.

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.METHODS: We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.RESULTS: The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.DISCUSSION: Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.

AB - INTRODUCTION: Children with diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis, with a median overall survival of 9 months. Our aims are to determine the incidence of DIPG in the Netherlands and to identify points for improvement in clinical research, a prerequisite for increasing the chance to find a cure.METHODS: We performed a population-based retrospective cohort study by evaluating all children diagnosed with DIPG in the Netherlands between 1990 and 2010.RESULTS: The incidence of DIPG in the Netherlands corresponds with international literature. Between 1990 and 2010, a large heterogeneity of treatment schedules was applied and only a minority of patients was included in clinical trials.DISCUSSION: Given the rarity of DIPG, we emphasize the need for (inter-)national trials to facilitate the identification of potentially effective therapeutics in the future. This can be supported by the recent development of a European DIPG registry enabling international study collaborations.

KW - Brain Stem Neoplasms/diagnosis

KW - Child

KW - Child, Preschool

KW - Cohort Studies

KW - Female

KW - Glioma/diagnosis

KW - Humans

KW - Male

KW - Netherlands

KW - Pons/pathology

KW - Prognosis

KW - Retrospective Studies

KW - Survival Rate

U2 - 10.1586/14737140.2015.974563

DO - 10.1586/14737140.2015.974563

M3 - Article

C2 - 25435089

SN - 1473-7140

VL - 15

SP - 157

EP - 164

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 2

ER -